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Background: To study the distribution pattern of lymph node metastases of stage IA to IIA cervical cancer and to
clarify the individualized clinical target volume delineation of regional lymph nodes (CTVn).
Methods: A total of 665 cases with International Federation Gynecology and Obstetrics stage IA to IIA cervical
cancer who underwent radical hysterectomy and pelvic lymphadenectomy were retrospectively reviewed. The
clinicopathological factors related to lymph node metastases were analyzed using logistic regression analysis.
Results: Pelvic lymph node metastases were found in 168 of 665 patients resulting in a metastasis rate of 25.3%.
Binary logistic regression analysis showed that age, lymph vascular space involvement, and deep stromal invasion
statistically influenced pelvic lymph node metastases (p = 0.017, < 0.001, < 0.001, respectively). Pathological
morphology type, lymph node metastases of the obturator, the external iliac and internal iliac, and the para-aortic
had a strong influence on lymph node metastases of the common iliac (p = 0.022, 0.003, < 0.001, 0.009, respectively).
Tumor size and lymph node metastases of the common iliac were significantly related to lymph node metastases
of the para-aortic (p = 0.045, < 0.001, respectively). Lymph node metastases of the obturator, the external iliac and
internal iliac were strongly correlated to lymph node metastases of the circumflex iliac node distal to the external
iliac node (CINDEIN; p = 0.027, 0.024, respectively).
Conclusions: Factors related to lymph node metastases should be comprehensively considered to design and
tailor CTVn for radiotherapy of cervical cancer. Selective regional irradiation including the correlated lymphatic
drainage regions should be performed.
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Cervical cancer is the most common gynecological ma-
lignancy and the second most frequent cause of cancer
death in Chinese women [1]. Radical hysterectomy and
pelvic lymphadenectomy are the standard treatment for
early stage cervical cancer. Postoperative radiotherapy is* Correspondence: shengxiugui@163.com
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patients with high-risk factors. Generally, patients with
risk factors, such as positive pelvic nodes, parametrial
invasion, or a positive vaginal margin are regarded as be-
ing at a “high risk” of recurrence [2].
Although the status of pelvic lymph nodes is not in-
cluded in International Federation Gynecology and
Obstetrics (FIGO) stage, it is one of the most important
prognostic factors and also an indicator of the need for
postoperative radiotherapy [3]. The study of risk factors
related to lymph node metastases can help identifyis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
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g/publicdomain/zero/1.0/) applies to the data made available in this article,
Li et al. Radiation Oncology  (2015) 10:40 Page 2 of 7patients who are more likely to have involved lymph
nodes, and to guide individualized radiotherapy. Taylor
et al. mentioned that inclusion of all pelvic lymph nodes
in the clinical target volume (CTV) may not be neces-
sary for all patients [4]. Accurate target definition is
vitally important to ensure that the target is not over- or
under-treated, and the dose to surrounding normal tis-
sues is limited. However, there are no detailed guidelines
on the personalized delineation of radiotherapeutic clin-
ical target volume for cervical cancer patients with rad-
ical hysterectomy and pelvic lymphadenectomy. In the
present study, we analyzed the pattern of lymph node
metastases in patients who had undergone radical hys-
terectomy and pelvic lymphadenectomy. The impact of
lymph node metastasis on radiotherapeutic clinical tar-
get volume delineation of regional lymph nodes (CTVn)
in cervical cancer was also investigated.
Methods
We retrospectively studied 665 patients with 2009 FIGO
[5] stage IA to IIA cervical cancer who had undergone
radical hysterectomy and systematic lymphadenectomy at
the Department of Gynecologic Oncology in Shandong
Cancer Hospital between June 1999 and October 2013.
The preoperative work-up included a complete history
and physical examination. Computed tomography (CT)/
X-ray (96.1%) of the chest and ultrasonography/CT
(96.1%) of the abdomen, or positron emission tomography
(PET)/CT (10.1%) were performed to exclude distant
organ metastasis. Other essential conditions included Kar-
nofsky Performance Scale (KPS) ≥ 70, with no preoperative
chemotherapy and/or radiotherapy. Clinical and patho-
logical data, including age, tumor size, FIGO stage, histo-
logical type, grade, deep stromal invasion, pathological
morphology type, and lymph vascular space involvement
(LVSI) were examined. Also included was the number of
regional lymph nodes and the number of regional lymph
nodes with metastases.
All patients underwent radical hysterectomy and bilat-
eral pelvic lymphadenectomy by gynecologic oncologists.
Para-aortic lymphadenectomy is not routinely performed
in patients with cervical carcinoma during radical hysterec-
tomy because the procedure increases both the morbidity
and the operation time. The para-aortic lymphadenectomy
was performed when there were positive pelvic nodes in
the frozen section or when there were suspicious or en-
larged pelvic or para-aortic lymph nodes, as determined by
intraoperative palpation. Lymph tissues were completely
removed along the common iliac, external iliac, and in-
ternal iliac vessels from above the common iliac bifur-
cation to the supra-inguinal ligament on both sides. In the
present study, we grouped the dissected lymph nodes into
six categories: the parametrial group is from vaginal cuff to
medial edge of the internal obturator muscle/ischial ramuson each side; the obturator group is removed superior to
the level of the obturator nerve; the external iliac and in-
ternal iliac group is located along the external and internal
iliac arteries between the inguinal canal and below the bi-
furcation of the common iliac artery; the common iliac
group is defined as the bifurcation level of the aorta to the
bifurcation of common iliac arteries into external and in-
ternal iliac arteries; the circumflex iliac node distal to the
external iliac node (CINDEIN) group is located between
the inguinal ligament and the deep circumflex vein; the
para-aortic group is from the level of the aortic bifurcation
up to the level of renal vessels. Dissected lymphatic tissues
were placed in different specimen bottles according to
their origin and sent for pathological evaluation. The
number of lymph nodes was evaluated and recorded by
two pathologists.
Statistics
The clinicopathological factors likely to influence lymph
node metastasis in cervical cancer, including age, tumor
size, FIGO stage, histological type, grade, deep stromal
invasion, pathological morphology type, and LVSI were
entered into statistical analysis. All parameters, such as
odds ratio (OR) and 95% confidence interval (CI), were
calculated with respect to their relationship with cervical
cancer lymph node metastasis using forward step-wise
binary logistic regression . All statistical tests were two-
sided and p < 0.05 was considered statistically significant.
All statistical analyses were performed using SPSS Statis-
tics (Version 17.0; SPSS Inc., Chicago, IL, USA).
Results
Patients and clinicopathological features
A total of 665 patients were included in the present
study. The median age was 44 years (range 22–77 years).
In total, 3.3% of patients were FIGO stage IA1, 1.1%
stage IA2, 22.2% stage IB1, 16.1% stage IB2, 29.9% stage
IIA1, and 27.4% stage IIA2. There were 491 (73.8%)
squamous cell carcinomas, 139 (20.9%) adenocarcin-
omas, and 35 (5.3%) other types of malignancies. Tumor
diameter was less than 4 cm in 387 (58.2%) and larger
than 4 cm in 278 (41.8%) patients. In terms of macro-
scopic types, there were 636 (95.6%) patients with exo-
phytic type and 29 (4.4%) with endophytic type. Deep
stromal invasion was present in 49.5% of the patients.
The percentage of patients with positive LVSI was
10.8%. The clinical and pathological characteristics of all
665 patients are shown in Table 1.
Overall pattern of lymph node metastases
The median number of dissected lymph nodes was 19,
with a range of 14–54. Pelvic lymph node metastases
were found in 168 patients with a metastasis rate of
25.3%. The most common site for pelvic lymph node
Table 1 Clinicopathological features
Characteristics N = 665
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tients), followed by the external iliac and internal iliac
nodes (13.4%; 89 of 665 patients), common iliac nodes
(3.6%; 24 of 665 patients), CINDEIN (2.6%; 17 of 665 pa-
tients), and parametrial nodes (1.8%; 12 of 665 patients).
Metastases to the para-aortic (1.7%; 11 of 665 patients)
and sacral nodes (0.6%; 4 of 665 patients) were relatively
rare. The rates of lymph node metastasis in different
groups of cervical cancer are shown in Figure 1.
Factors associated with pelvic lymph node metastases
The relationships between pelvic lymph node metastasis
rate and various clinical characteristics are shown in
Table 2. We entered age, tumor size, macroscopic type,
FIGO stage, histological type, grade, deep stromal inva-
sion, pathological morphology type, and LVSI into thebinary logistic statistical analysis. The results showed that
age, deep stromal invasion, and LVSI had a statistical influ-
ence on pelvic lymph node metastases, while age decreased
the risk of lymph node metastases (p = 0.017, OR = 0.975,
95% CI = 0.955–0.996). On the contrary, deep stromal inva-
sion and LVSI increased the risk of lymph node metastases
(p < 0.001, < 0.001, respectively; OR = 2.930, 3.967, respect-
ively; 95% CI = 2.006–4.280, 2.358–6.674, respectively).
Factors associated with common iliac, para-aortic, and
CINDEIN lymph node metastases
Table 3 shows the result of the multivariate analysis for
factors associated with common iliac, para-aortic, and
CINDEIN lymph node metastases. The binary logistic
regression analysis showed that lymph node metastases
of the common iliac was strongly influenced by patho-
logical morphology type, lymph node metastases of the
obturator, the external iliac and internal iliac, and the
para-aortic (p = 0.022, 0.003, < 0.001, 0.009, respectively;
OR = 5.572, 1.667, 1.858, 3.215, respectively; 95% CI =
1.285–24.16, 1.185–2.345, 1.345-2.566, 1.343–7.695, re-
spectively). Tumor size and lymph node metastases of
the common iliac were significantly related with lymph
node metastases of the para-aortic (p = 0.045, < 0.001,
respectively; OR = 5.165, 1.593, respectively; 95% CI =
1.036–25.76, 1.277–1.988, respectively). Lymph node
metastases of the obturator, the external iliac and in-
ternal iliac were statistically correlated with CINDEIN
lymph node metastases (p = 0.027, 0.024, respectively;
OR = 1.419, 1.403, respectively; 95% CI = 1.041–1.934,
1.046–1.882, respectively).
Discussion
Cervical cancer is clinically classified according to the
FIGO clinical staging system, which does not include
evaluation of lymph node status. However, lymphatic
channel dissemination is one of common methods of
cervical cancer spread. Lymph node status is the most
important prognostic factor and has an immense impact
on the subsequent determination of adjuvant therapy in
early cervical carcinoma [6]. In a report by Peters et al.
[7], recurrences are much more frequent in patients with
lymph node involvement, and concurrent cisplatin-based
chemotherapy (with or without 5-fluorouracil) together
with pelvic irradiation is superior to radiation alone in
improving progression-free and overall survival. Never-
theless, several studies have shown [7-12] that patients
benefited from concurrent cisplatin with pelvic radio-
therapy, but they also suffered from treatment toxicities.
Acute grade 3–4 nonhematologic toxicity was present in
23.4% and chronic grade 4 toxicity was present in 5% of
patients with postoperative chemo-radiation therapy [7,8].
Whitney et al. [9] pointed out that the late complication
(grade 3–4) rate is up to 16.2% with cisplatin-based
Figure 1 Distribution of positive PLN in stage 1 A to 11 A cervical cancer.
Li et al. Radiation Oncology  (2015) 10:40 Page 4 of 7chemotherapy at 3 years in their study of stage IIB-IVA
cervical cancer with negative para-aortic lymph nodes.
These toxicity rates increase when chemotherapy and ex-
tended field radiotherapy are combined, and the rate of
acute nonhematologic grade 3–4 toxicity was 81%, while
chronic grade 3–4 toxicity was 40% with follow-up up to
38 months [10]. Despite the already high toxicity, the situ-
ation may worsen with time. Grade 3 toxicities at 3 and
5 years were 7.7% and 9.3%, but increased approximately
0.34% per year through 10–20 years in a retrospective ana-
lysis of 1,784 cervical cancer patients who were treated
with radiation [11]. This underlines the need for improve-
ments in radiotherapy delivery. One way to accomplish
this is with the application of intensity-modulated radio-
therapy (IMRT) particularly suitable for cervical cancer
with irregular irradiation field. IMRT has been shown to
reduce the incidence of acute and late toxicities and has
been associated with low rates of in-field failures [13-15].
Mundt et al. [16,17] published results of patients treated
with IMRT versus conventional radiotherapy. Grade 2
gastrointestinal symptoms were reduced from 91% to 60%
and late gastrointestinal toxicity decreased from 50% toTable 2 Multivariate analysis of risk factors associated with ly
B S.E Wald
Age −0.025 0.011 5.680
Deep stromal invasion 1.075 0.193 30.95
LVSI 1.378 0.265 26.95
Constant −1.871 0.509 13.53
Abbreviation: LVSI lymph vascular space involvement, OR odds ratios, CI confidence11.1%. IMRT should be applied and combined with
chemotherapy to reduce complications and improve the
local control rates of cervical cancer patients. Another
way to achieve this task is with accurate delineation of the
target volume. Accurate target delineation is very import-
ant to avoid over-treatment. An over-treated target can in-
crease the doses of normal tissues and result in more
complications. However, at present, there are no consen-
sus guidelines on the basis of different risk factors for the
optimal delineation of radiotherapeutic CTVn of IMRT
for cervical cancer patients with radical hysterectomy and
lymphadenectomy. In the present study, we retrospectively
examined 665 cervical cancer patients who had undergone
radical hysterectomy and lymphadenectomy, and analyzed
patterns of lymph node metastases. From these results, we
intended to obtain useful information on how to define in-
dividualized CTVn for patients with cervical cancer who
are slated to undergo IMRT.
In the present study, the most common site for pelvic
lymph node metastases was the obturator, at a rate of
17.6%, followed by the external iliac and internal iliac
(13.4%), common iliac (3.6%), and CINDEIN (2.6%).mph node metastase
df p value OR 95% CI for OR
1 0.017 0.975 0.955-0.996
1 <0.001 2.930 2.006-4.280
1 <0.001 3.967 2.358-6.674
1 <0.001 0.154
interval.
Table 3 Multivariate analysis of risk factors associated with common iliac, para-aortic lymph node and CINDEIN
metastases in cervical cancer
Group Parameters B S.E Wals df p value OR 95% CI for OR
Common iliac Pathologic morphology type 1.718 0.748 5.268 1 0.022 5.572 1.285-24.16
LNM of obturator 0.511 0.174 8.630 1 0.003 1.667 1.185-2.345
LNM of external iliac and internal iliac 0.619 0.165 14.10 1 <0.001 1.858 1.345-2.566
LNM of para-aortic 1.168 0.445 6.881 1 0.009 3.215 1.343-7.695
Para-aortic Tumor size 1.642 0.820 4.011 1 0.045 5.165 1.036-25.76
LNM of common iliac 0.466 0.113 17.05 1 <0.001 1.593 1.277-1.988
CINDEIN LNM of obturator 0.350 0.158 4.905 1 0.027 1.419 1.041-1.934
LNM of external iliac and internal iliac 0.339 0.150 5.121 1 0.024 1.403 1.046-1.882
Abbreviation: LNM lymph node metastases, CINDEIN circumflexiliac node distal to the external iliac node, OR odds ratios, CI confidence interval.
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presacral nodes (0.6%) were relatively rare. Our results
confirmed the findings of Sakuragi et al. [18]. It has been
shown that the depth of LVSI [18,19] and deep stromal
invasion [18] are associated with lymphatic metastases
in cervical cancer in previous studies. Similarly, our re-
sults suggested that independent prognostic factors for
lymph node metastases include LVSI (p < 0.001) and
deep stromal invasion (p < 0.001). Furthermore, we also
found that age was a significant predictor of lymph node
metastases (p = 0.017). The age range of patients in this
study was 22 to 77 years old, and they were arbitrarily
divided into two age groups, 40 years and under, and >
40 years. The percentage of positive nodes was higher in
the younger group compared with the older group (≤
40 years, 27.9% positive versus > 40 years, 23.7%). Our
results showed that old age was a protective factor for
lymph node metastases. However, this finding does not
mean that older patients have lower risks of cervical
cancer lymph node metastases, but our results empha-
sized the important role of age in cervical cancer lymph
node metastases.
According to the distribution pattern of lymph node
metastasis described above, personalized delineation of
CTVn on the basis of different risk factors was consid-
ered. National Comprehensive Cancer Network (NCCN)
Clinical Practice Guidelines (2013) [20] in cervical can-
cer provided us definitive guidelines for postoperative
patients with negative nodes who would undergo radio-
therapy. Using these guides, the radiation lymph region
should at least include the parametria, presacral, obtur-
ator, internal iliac, and external iliac nodal regions
whether or not lymph nodes are involved. Therefore,
CTVn mainly focused on the common iliac, para-aortic,
and CINDEIN in our present study. Although the
NCCN (2013) [20] and the Radiation Therapy Oncology
Group (RTOG; 2008) [21] achieved some consensus
guidelines on a CTV definition for intensity-modulated
pelvic radiotherapy for the postoperative treatment ofcervical cancer, they mainly defined margins and rarely
mentioned how to perform selective regional irradiation
with different risk factors. The results of our subgroup
analysis suggested that radiation oncologists should de-
sign individualized radiotherapeutic CTVns for cervical
cancer patients with different risk factors.
Our subgroup analysis suggested that endophytic tu-
mors were associated with an increased risk of common
iliac lymph node metastasis. Our results emphasized the
importance of pathological morphology type in cervical
cancer lymph node metastases. Although common iliac
node metastases are rare in early stage carcinomas in
the absence of positive pelvic nodes [22], they should be
included in CTVn for cervical cancer patients with
endophytic tumors. Previous reports showed that posi-
tive lymph nodes are seldom found in the common iliac
lymph area unless the pelvic nodes are involved, but they
didn’t describe in detail which group involved would sta-
tistically increase risk [18,23]. Our study revealed that
common iliac involvement was influenced by lymph node
metastases of the obturator, the external iliac and internal
iliac, and the para-aortic (p = 0.003, < 0.001, 0.009, re-
spectively). We recommended delineating common iliac
nodal region when these three above-mentioned groups
are involved.
The survival outcome of cervical cancer patients with
positive para-aortic lymph nodes is poor; a 30% 5-year
survival has been demonstrated in a retrospective study
of these patients [24]. Pelvic radiation therapy was re-
quired to improve survival rates with cure in 60% to
70% of Stage IIB [25], but there was a high incidence of
gastrointestinal toxicity with conventional extended field
radiotherapy and the dose is usually limited to 45 Gy be-
cause of normal tissue dose limitations. Portelance et al.
[26] reported a 30% to 70% reduction in dose to organs
at risk (OARs) with IMRT compared with a conventional
four-field technique. Early data on the use of extended
field IMRT and concurrent cisplatin chemotherapy was
encouraging, with less late gastrointestinal morbidity
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taneous integrated boost (SIB) IMRT for dose escalation
to involved nodes [13,27,28]. Although IMRT can in-
crease the dose to the target and reduce the dose in nor-
mal tissues, accurate delineation is very important for
IMRT to ensure that the target is not under- or over-
treatment. IMRT together with accurate delineation can
further decrease complications yet retain efficacy. We
found that tumor size and lymph node metastasis of the
common iliac were associated with lymph node metasta-
sis of the para-aortic. Our results were partially consist-
ent with a previously published study [23] that showed
that tumor size was a prognostic factor of lymph node
metastasis of the para-aortic (p < 0.01). Presence of pel-
vic lymph node metastasis increases the risk of para-
aortic involvement in several studies [18,22,23,29]. In
our study, we found that common iliac involvement pre-
dicted para-aortic lymph node metastasis. When tumor
size was > 4 cm or lymph node metastasis of the com-
mon iliac is indicated, we recommend including the
para-aortic lymph nodes in the treatment volume.
CINDEIN, which is the most distal external iliac
lymph node in the pelvic cavity, has been called the lat-
eral deep inguinal node [18], suprainguinal node [29],
circumflex iliac node [30], and distal external iliac lymph
node [31] in the literature. This group of lymph nodes is
usually included in CTV in previous studies [32,33], but
seldom mentioned with specific contouring recommen-
dations. Several reports, including our previous study
[29,31,34], have described the incidence of the CINDEIN
metastasis in cervical cancer from 2.5% to 8% and have
demonstrated that CINDEIN is seldom involved in me-
tastasis. In the present study, we found that 17 of 665
patients had CINDEIN involvement and the incidence of
CINDEIN metastases was 2.6%. Of these 17 patients, 16
had obturator or internal and external iliac involvement,
while only one patient without other groups of lymph
node metastases had positive CINDEIN. Patients with-
out CINDEIN involvement was 97.4% (648 of 665). Of
these 648 patients, 146 had obturator or internal and ex-
ternal iliac involvement, 2 had isolated parametrial node
involvement, 2 had isolated common iliac involvement,
and 498 had negative lymph node. The negative predict-
ive value of the negative other groups on CINDEIN me-
tastasis in patients with early stage cervical cancer was
therefore 99.8% (498 of 499 patients). Together with our
subgroup analysis, we definitively showed that the obtur-
ator involvement, and the internal and external iliac in-
volvement were risk factors for CINDEIN metastasis.
Thus, CINDEIN metastases might occur subsequently to
widespread pelvic lymph node metastasis, especially in
the obturator, and the external and internal iliac regions.
This is consistent with the routes of lymph flow from
the uterine cervix, as described in previous reports[35,36]. Therefore, CINDEIN is recommended to be con-
toured into CTV when the obturator or the internal and
external iliac become involved. Otherwise, it is not sug-
gested in CTV with negative obturator, internal and exter-
nal iliac lymph nodes, and especially with no lymph node
involvement.
Conclusion
CTVn must be customized by experienced oncologists
according to the various clinical factors that influence
lymph node metastasis. Irradiation of selective regional
lymph nodes and their correlated lymphatic drainage re-
gions should be performed according to clinical and
pathological factors, deep stromal invasion, and LVSI.
For large and endophytic tumors, the irradiation field
should be enlarged appropriately. Our results can im-
prove the accuracy of postoperative adjuvant therapy
and allow a more individualized treatment for cervical
cancer patients.
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